NASDAQ:MRUS - Merus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has decreased by 20.2% and is now trading at $11.60. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for Merus.

4 analysts have issued 1 year price targets for Merus' shares. Their forecasts range from $20.00 to $25.00. On average, they anticipate Merus' share price to reach $23.25 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price. View analysts' price targets for Merus.

News coverage about MRUS stock has trended very negative on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutMerus.

Some companies that are related to Merus include Karyopharm Therapeutics (KPTI), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST), Ligand Pharmaceuticals (LGND), Innoviva (INVA), I-Mab (ARQT), ZEALAND PHARMA/S (ZEAL), Zogenix (ZGNX), Tricida (TCDA), TG Therapeutics (TGTX), Heron Therapeutics (HRTX), Amneal Pharmaceuticals (AMRX), Y-mAbs Therapeutics (YMAB), Enanta Pharmaceuticals (ENTA) and Akebia Therapeutics (AKBA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Viking Therapeutics (VKTX), AT&T (T), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), GlycoMimetics (GLYC) and Idera Pharmaceuticals (IDRA).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $11.60.

Merus has a market capitalization of $336.40 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe. View additional information about Merus.

The official website for Merus is http://www.merus.nl/.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]